Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co KGaA    FRE   DE0005785604

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Fresenius Sets Pricing On EUR500 Million 7-Year Bond At 4.25% Area

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/21/2012 | 01:24pm CEST

("Fresenius Sets Pricing On EUR500M 7-Year Bond At 4.25% Area," at 1020 GMT, misstated the vehicle issuing the bond in the first paragraph. The correct version follows:)

-German medical care company Fresenius SE & CO. KGaA (>> Fresenius SE & Co KGaA) has set price guidance on its EUR500 million seven-year bond in the area of 4.25%, one of the banks on the deal said Wednesday.

The issue will be priced later Wednesday, and books on the deal are comfortably oversubscribed, said one of the banks on the deal. The issue was primarily targeted at retail accounts, which showed a good deal of interest, it added.

The bond will be used--among other corporate purposes--to fund the acquisition of hospital operator Damp Group, which Fresenius acquired in October 2011.

Expected ratings are Ba1 from Moody's Investors Service and BB+ from Standard & Poor's Corp. and Fitch Ratings.

Royal Bank of Scotland Group PLC, Deutsche Bank AG, Commerzbank AG, LBBW and Bayern LB are lead managers on the deal.

-By Serena Ruffoni, Dow Jones Newswires; +44 (0) 207 842 9349; [email protected]

Stocks mentioned in the article : Fresenius SE & Co KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS SE & CO KGAA
04/25 Fresenius picks up M&A pace with Akorn, Merck KGaA deals
04/25DJFRESENIUS : Makes Two Acquisitions to Boost Kabi Clinical Unit
04/24DJFresenius Kabi To Strengthen And Diversify Product Portfolio By Acquiring Ako..
04/08DJFRESENIUS : in Talks to Buy U.S. Drug Maker Akorn -- Update
04/08DJFRESENIUS : Germany's Fresenius in Talks to Buy U.S. Pharmaceuticals Maker Akorn
04/07DJFRESENIUS : Confirms Discussions With Akorn, Inc.
02/20DJFRESENIUS : 4Q 2016 -- Forecast
02/02 FRESENIUS : Initial conversion price of equity-neutral convertible bonds fixed
01/31 FRESENIUS : Helios closes acquisition of Quirónsalud
01/23 FRESENIUS : Denco Area 9-1-1 achieves CALEA accreditation
More news
Sector news : Hospitals, Clinics & Primary Care Services
04/27 European shares fall as ECB stands pat, banks drop
04/17DJPLEASE DISREGARD HCA REVENUE, NET IN : 30 a.m. ET
04/12 FTSE slips from three-week highs as Tesco slumps
04/12 Denmark's Novo A/S ups Synlab stake to 20 percent before possible IPO
04/04 FTSE leads European peers as energy and industrials stocks gain
More sector news : Hospitals, Clinics & Primary Care Services
News from SeekingAlpha
04/26 Fresenius Shows Biotech How To Get The Deals Done
04/15 The Market Is Going To Fall - My Dividend Growth Shopping List
04/11 First-Quarter Deal Making Shows Glimmers Of Growth
04/10 Fresenius Is A Highly Strategic Buyer For Akorn
04/10 FOCUS ON EUROPE : Will An Akorn - Fresenius Deal Pass Anti-Trust Scrutiny?
Advertisement
Financials (€)
Sales 2017 34 246 M
EBIT 2017 5 061 M
Net income 2017 1 901 M
Debt 2017 17 270 M
Yield 2017 0,99%
P/E ratio 2017 21,98
P/E ratio 2018 19,78
EV / Sales 2017 1,72x
EV / Sales 2018 1,56x
Capitalization 41 662 M
More Financials
Chart FRESENIUS SE & CO KGAA
Duration : Period :
Fresenius SE & Co KGaA Technical Analysis Chart | FRE | DE0005785604 | 4-Traders
Full-screen chart
Technical analysis trends FRESENIUS SE & CO...
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 81,3 €
Spread / Average Target 8,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Niko Stumpfögger Member-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Rainer Stein Member-Supervisory Board
Michael Albrecht Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
FRESENIUS SE & CO KGAA1.36%45 252
IHH HEALTHCARE BHD--.--%11 738
RAMSAY HEALTH CARE LIM..1.77%10 727
BANGKOK DUSIT MEDICAL ..--.--%9 141
MEDICLINIC INTERNATION..11.41%8 173
ENVISION HEALTHCARE CO..-12.48%6 510
More Results